Blood Monocyte Subsets and Selected Cardiovascular Risk Markers in Rheumatoid Arthritis of Short Duration in relation to Disease Activity
Table 4
Monocyte subpopulations and their characteristics (total count, expression of HLA-DR, CD45RA, and -integrins) according to DAS28.
Control group ( = 22)
RA patients with low ( = 14)
RA patients with high ( = 10)
value
Mean (SD)
Mean (SD)
Mean (SD)
Monocytes total count (per L of blood)
387.14 (110.15)
508.57 (240.63)
661.00 (194.90)*
0.001
CD14++CD16− classical monocytes
CD45RA, MFI
780.30 (293.99)
621.00 (132.48)
696.70 (250.78)
0.174
CD11c, MFI
1286.57 (1072.39)
1448.64 (527.74)
1662.20 (722.06)
0.526
CD11b, MFI
1707.85 (1816.07)
1281.42 (684.76)
1644.80 (1087.00)
0.665
HLA-DR, MFI
6116.86 (2040.72)
9559.00 (4229.12)*
5628.70 (2141.07)#
0.001
CD14++CD16+ intermediate monocytes
CD45RA, MFI
1079.45 (594.60)
680.71 (161.28)
756.80 (253.02)
0.023
CD11c, MFI
2877.95 (2235.30)
2645.50 (874.77)
2886.20 (1051.87)
0.910
CD11b, MFI
1937.57 (2182.40)
1428.57 (786.51)
1798.60 (1134.00)
0.670
HLA-DR, MFI
30188.32 (7584.79)
31106.93 (8237.30)
21746.10 (8066.17)
0.011
CD14+CD16++ nonclassical monocytes
CD45RA, MFI
3512.00 (2599.85)
1764.64 (405.46)
2281.00 (713.70)
0.157
CD11c, MFI
3532.42 (2599.85)
4235.21 (1422.03)
5655.50 (2402.56)
0.060
CD11b, MFI
855.19 (738.51)
696.64 (368.87)
762.00 (317.71)
0.715
HLA-DR, MFI
21097.32 (8487.21)
35553.21 (11818.02)*
28167.20 (11481.66)
<0.001
Data are shown as means (SD). Low DAS28 = (2.6–5.1); high DAS28 = (>5.1). RA: rheumatoid arthritis; MFI: mean fluorescence intensity. value in ANOVA (GLM models). * versus control group, # versus RA patients with low disease activity in post-hoc analyses.
